Trevi Therapeutics has announced significant milestones in its clinical programs for Haduvio (nalbuphine), an investigational therapy aimed at treating chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC). 4 October 2024
Paris-based asset manager Kurma Partners has raised 140 million euros ($154 million), successfully completing the first closing of Biofund IV 4 October 2024
Singapore’s Agency for Science, Technology and Research (A*STAR) and US biotech incubator Flagship Pioneering have agree to collaborate on advancing health and sustainability outcomes in Singapore and the broader Asia Pacific region. 4 October 2024
The US Food and Drug Administration (FDA) has removed the partial clinical hold on delpacibart etedesiran (del-desiran/AOC 1001), an investigational treatment designed to address the root cause of myotonic dystrophy type 1 (DM1), under development by US biotech Avidity Biosciences . 4 October 2024
Caliway Biopharmaceuticals has successfully completed its initial public offering, raising NT$6.4 billion ($206 million), the largest IPO in Taiwan's biotech industry to date. 3 October 2024
US clinical-stage biotech Arcus Biosciences has entered into a clinical trial collaboration with AstraZeneca on renal cancer treatments. 3 October 2024
PeptiDream says that its wholly-owned PDRadiopharma subsidiary has entered into a strategic partnership with French nuclear medicines firm Curium. 3 October 2024
Shares of UK drug developer Hemogenyx Pharmaceuticals rose as much as 9% and closed up 5.9% at 1.70 pence yesterday on the news of a further investment from Prevail Partners. 3 October 2024
UK-based biotech Resolution Therapeutics has announced the completion of a £63.5 million ($76.8 million) series B financing round led by Syncona. 3 October 2024
Liquidia Corporation and Pharmosa Biopharm have amended the current exclusive licensing agreement for the development and commercialization of L606. 3 October 2024
Timing can be crucial in biotech, and any company that can help optimize radiopharmaceuticals to fight cancer is likely to a hot property right now, given the recent popularity of the field among investors and drugmakers. 2 October 2024
UK-based biotech LoQus23 Therapeutics has closed a £35 million ($43 million) series A financing round, led by Forbion, with support from SV Health Investors' Dementia Discovery Fund and Novartis Venture Fund. 2 October 2024
Privately-held UK biotech Curve Therapeutics today announced the further strengthening of its leadership team with the appointments of Andre Hoekema as chairman of the board and Cora Griffin as head of business development. 2 October 2024
NK:IO, a London startup developing a cell therapy for treating solid tumors, has announced the appointment of a permant chief executive and the finalization of a seed funding round. 2 October 2024
Spanish epigenetics firm Oryzon Genomics has announced the receipt of the official meeting minutes from a recent End-of-Phase II meeting for vafidemstat in borderline personality disorder (BPD) with the US Food and Drug Administration (FDA). 2 October 2024
Halda Therapeutics, a US biotech company advancing cancer treatments, announced the appointment of Christian Schade as president and chief executive. 1 October 2024
US biopharma company Intercept Pharmaceuticals yesterday announced positive top-line results from a new interim analysis of its ongoing pivotal Phase III REGENERATE trial of obeticholic acid (OCA) in patients with liver fibrosis due to non-alcoholic steatohepatitis (NASH). 8 July 2022
Sino-American company Brii Biosciences announced the commercial launch of the amubarvimab/romlusevimab (previously BRII-196/BRII-198) combination, a long-acting COVID-19 neutralizing antibody therapy, in China. 8 July 2022
Swedish Orphan Biovitrum, also known as Sobi, today announced an exclusive license agreement with Swiss firm ADC Therapeutics to develop and commercialize loncastuximab tesirine for use in hematology and other indications of large unmet medical need in Europe and most international markets. 8 July 2022
US oncology biotech CytomX Therapeutics’ shares were down more than 25% at $1.47 in pre-market trading, after the company revealed that the latest clinical data on its praluzatamab ravtansine did not support further development alone. 7 July 2022
USA-based immuno-oncology company Portage Biotech has signed an agreement to acquire Tarus Therapeutics, a private company developing adenosine receptor antagonists. 7 July 2022
Shares in Minneapolis-based DiaMedica Therapeutics, a biopharma focused on developing novel treatments for neurological disorders and kidney diseases, were down by a third in pre-market trading on Thursday. 7 July 2022
Privately-held US biotech Skyhawk Therapeutics has announced an exclusive worldwide collaboration agreement with French pharma major Sanofi to discover and develop novel small molecules that modulate RNA splicing for challenging oncology and immunology targets. 6 July 2022
Urovant Sciences has entered into an exclusive license agreement with French drugmaker Pierre Fabre to register and commercialize vibegron, trade named Gemtesa, for the treatment of overactive bladder (OAB) in certain countries. 5 July 2022
Gene expression company Syros Pharmaceuticals is to acquire TYME Technologies in a deal that values the oncology-focused biotech at around $60 million. 5 July 2022
Germany’s CureVa is the latest biopharma company seeking to get a share of the very large profits being made by the most successful COVID-19 vaccines and treatments. 5 July 2022
In line with its commitment to transparency, Spanish plasma-derived medicines company Grifols has disclosed for the seventh consecutive year all payments and other transfers of value related to medicines and medical technology made to healthcare professionals and healthcare organizations in the several European countries listed within the European Federation of Pharmaceutical Industries and Associations’ (EFPIA) scope, including Spain. 5 July 2022
The original news that Japan’s Otsuka had decided to give back rights to vadadustat to Akebia Therapeutics caused the US firm’s shares to slump. However, the disclosure that, as part of the termination, Otsuka has agreed to pay Akebia a settlement fee of $55 million saw its stock leap as much as 40% to $0.50 pre-market on Friday. 2 July 2022
Angion Biomedica saw its shares close down 33% on Thursday and fall a further 6% to $1.07 pre-market today, after the US company announced it will discontinue the Phase II JUNIPER study of ANG-3070 in patients with primary proteinuric kidney diseases. 1 July 2022
Danish biotech company Genmab has announced its intent to submit a biologics license application (BLA) to the US Food and Drug Administration (FDA) for subcutaneous epcoritamab (DuoBody-CD3xCD20), an investigational bispecific antibody, for the treatment of patients with relapsed/refractory large B-cell lymphoma (LBCL), in the second half of 2022. 1 July 2022
The US Food and Drug Administration (FDA) yesterday issued a warning that results from a clinical trial show a possible increased risk of death with Copiktra (duvelisib) compared to another medicine to treat a chronic blood cancer called leukemia and a lymphoma, a cancer found in the lymph nodes. 1 July 2022
NewAmsterdam Pharma, a Dutch clinical-stage company focused on the research and development of transformative therapies for cardio-metabolic diseases, and privately-held Italian Menarini Group have announced an exclusive license agreement for the commercialization of obicetrapib. 29 June 2022
Switzerland-based Roivant Sciences, which has a long history of creating new companies, has now unveiled Priovant Therapeutics, this time in collaboration with US pharma giant Pfizer, dedicated to developing and commercializing novel therapies for autoimmune diseases with the greatest morbidity and mortality. 28 June 2022
Shares of Swiss biotech Basilea Pharmaceutica gained more than 3% to 38.45 francs yesterday, after it announced an update on the progress made in the implementation of its strategic focus on anti-infectives. 28 June 2022
Canadian clinical-stage biotech Zymeworks today announced that it is strengthening its senior leadership team with the appointment of Paul Moore, as chief scientific officer, reporting directly to the chief executive Officer. 27 June 2022
French drugmaker Ipsen this morning announced it is to acquire US epigenetic therapies firm Epizyme in order to expand its oncology portfolio. 27 June 2022